UCLA researchers have discovered that nanodiamonds could be used to promote bone growth and the durability of dental implants. Nanodiamonds, which are created as byproducts of conventional mining and refining operations, are approximately 4 to 5 nanometers in diameter and are shaped like tiny soccer balls.
Scientists from the UCLA School of Dentistry, the UCLA Department of Bioengineering, and Northwestern University, along with collaborators at the NanoCarbon Research Institute in Japan, may have found a way to use them to improve bone growth and combat osteonecrosis, a potentially debilitating disease in which bones break down due to reduced blood flow.
When osteonecrosis affects the jaw, it can prevent people from eating and speaking; when it occurs near joints, it can restrict or preclude movement. Bone loss also occurs next to implants such as prosthetic joints or teeth, which leads to the implants becoming loose—or failing.
The study, led by Dr. Dean Ho, professor of oral biology and medicine and co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry, appears online in the Journal of Dental Research.
During bone repair operations, which are typically costly and time-consuming, doctors insert a sponge through invasive surgery to locally administer proteins that promote bone growth, such as bone morphogenic protein.
Ho's team discovered that using nanodiamonds to deliver these proteins has the potential to be more effective than the conventional approaches. The study found that nanodiamonds, which are invisible to the human eye, bind rapidly to both bone morphogenetic protein and fibroblast growth factor, demonstrating that the proteins can be simultaneously delivered using one vehicle. The unique surface of the diamonds allows the proteins to be delivered more slowly, which may allow the affected area to be treated for a longer period of time. Furthermore, the nanodiamonds can be administered non-invasively, such as by an injection or an oral rinse.
"We've conducted several comprehensive studies, in both cells and animal models, looking at the safety of the nanodiamond particles," said Laura Moore, the first author of the study and an MD-PhD student at Northwestern University under the mentorship of Dr. Ho. "Initial studies indicate that they are well tolerated, which further increases their potential in dental and bone repair applications."
"Nanodiamonds are versatile platforms," said Ho, who is also professor of bioengineering and a member of the Jonsson Comprehensive Cancer Center and the California NanoSystems Institute. "Because they are useful for delivering such a broad range of therapies, nanodiamonds have the potential to impact several other facets of oral, maxillofacial and orthopedic surgery, as well as regenerative medicine."
Ho's team previously showed that nanodiamonds in preclinical models were effective at treating multiple forms of cancer. Because osteonecrosis can be a side effect of chemotherapy, the group decided to examine whether nanodiamonds might help treat the bone loss as well. Results from the new study could open the door for this versatile material to be used to address multiple challenges in drug delivery, regenerative medicine and other fields.
"This discovery serves as a foundation for the future of nanotechnology in dentistry, orthopedics and other domains in medicine," said Dr. No-Hee Park, dean of the School of Dentistry. "Dr. Ho and his team have demonstrated the enormous potential of the nanodiamonds toward improving patient care. He is a pioneer in his field."
Other authors of the study were Professor Eiji Osawa of the NanoCarbon Research Institute in Japan; and Ho-Joong Kim, a postdoctoral research scholar who was previously in Dr. Ho's laboratory and is currently an assistant professor of chemistry at Chosun University in South Korea.
The study was supported by the National Cancer Institute, the National Science Foundation, the Wallace H. Coulter Foundation, The V Foundation for Cancer Research, the Society for Laboratory Automation and Screening, Beckman Coulter and the European Commission.